GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2007

Ciphergen and Quest Diagnostics to Develop PAD Diagnostic

  • Quest Diagnostics accepted a second development plan from Ciphergen under their existing strategic alliance agreement. In addition to the current ovarian tumor triage test, Quest Diagnostics will now also assist Ciphergen in the development of a blood-based assay for the detection of peripheral artery disease (PAD).

    Ciphergen is working with Stanford University to develop a blood test that will help physicians in the diagnosis of PAD. Similar to cardiovascular disease, PAD is caused by the buildup of fat and cholesterol in the peripheral arteries and disrupts normal bloodflow leading to stenosis.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Sustainability in New Dietary Guidelines

Do you think that sustainability considerations should be incorporated into the new Dietary Guidelines for Americans?

More »